Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.46USD
15 Dec 2017
Change (% chg)

$0.02 (+3.91%)
Prev Close
$0.44
Open
$0.44
Day's High
$0.46
Day's Low
$0.44
Volume
75,262
Avg. Vol
104,229
52-wk High
$1.39
52-wk Low
$0.38

Summary

Name Age Since Current Position

Thomas Meyer

48 Chairman of the Board, Chief Executive Officer

James Healy

52 2013 Non-Executive Independent Vice Chairman of the Board

Hernan Levett

2017 Chief Financial Officer

Anne Zoller

36 2015 General Counsel

Cindy McGee

2016 Head of Investor Relations and Corporate Communications

Andrea Braun

2016 Head of Regulatory and Quality Affairs

Thomas Jung

2016 Chief Development Officer

Bettina Stubinski

49 2013 Chief Medical Officer

Wolfgang Arnold

74 2007 Non-Executive Independent Director

Oliver Kubli

43 2010 Non-Executive Independent Director

Berndt Modig

58 2015 Non-Executive Independent Director

Calvin Roberts

63 2015 Non-Executive Independent Director

Biographies

Name Description

Thomas Meyer

Dr. Thomas Meyer serves as Chairman of the Board, Chief Executive Officer of Auris Medical Holding Ltd. Mr. Meyer founded Auris Medical in April 2003. Prior to founding us, he was the Chief Executive Officer of Disetronic Group, a leading Swiss supplier of precision infusion and injection systems. He worked for Disetronic in various functions starting in 1988, becoming member of the board of directors in 1996, Deputy Chief Executive Officer in 1999 and Chief Executive Officer in early 2000. Prior to joining Disetronic, he advised several Swiss companies in strategy, marketing and corporate finance. He holds a Ph.D. (Dr.rer.pol.) in business administration from the University of Fribourg, Switzerland.

James Healy

Dr. James I. Healy, M.D., Ph.D., serves as Non-Executive Independent Vice Chairman of the Board of Auris Medical Holding Ltd. Dr. Healy has been a member of our board of directors since April 2013. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Amarin Corporation, plc., Ascendis Pharma A/S, Coherus Bioscience, Inc., Edge Therapeutics, Inc. and several private companies. Previously, he served as a board member of Hyperion Therapeutics, Inc, CoTherix, Inc., Durata Therapeutics, Inc., InterMune, Inc. Movetis NV and several private companies. Dr. Healy was nominated to our board of directors by Sofinnova Ventures. Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford School of Medicine and holds a B.A. in molecular biology and a B.A. in Scandinavian Studies from the University of California at Berkeley.

Hernan Levett

Mr. Hernan Levett has been Chief Financial Officer of Auris Medical Holding Ltd. since January 2017. Prior to joining Auris Medical, Mr. Levett served as Head of Group Controlling at Acino Pharma AG and previously served as Vice President of Finance and Administration Europe at InterMune International AG. In addition, he spent 10 years at Novartis, most recently as Chief Financial Officer of Novartis Chile SA.

Anne Zoller

Ms. Anne Sabine Zoller serves as General Counsel of Auris Medical Holding Ltd. Ms. Zoller joined the Company as Senior Legal Counsel in April 2015 and was appointed General Counsel in August 2015. Prior to joining Auris Medical, Ms Zoller was a Corporate/M&A Counsel with Straumann Group, a dental implant company headquartered in Basel, and an attorney in the Corporate/M&A team of Homburger AG, a Zurich based law firm. She obtained a Ph.D. in law from the University of Zurich and holds an M.B.A. degree.

Cindy McGee

Ms. Cindy McGee serves as Head of Investor Relations and Corporate Communications of the company. Ms. McGee will direct and expand the Company's communication activities and further develop and foster relationships with the investment community and media. She previously held various positions with Arena Pharmaceuticals, including Vice President, Investor Relations and Alliance Management, and Ligand Pharmaceuticals and spent several years advising life science companies through her work at investor relations and communications agencies. Ms. McGee holds a BBA from the University of San Diego.

Andrea Braun

Ms. Andrea Braun is Head of Regulatory and Quality Affairs of the company. and member of the Executive Management Committee. In this newly created position, Ms. Braun will lead the Company's regulatory affairs, quality and pharmacovigilance activities. She will join Auris Medical in the coming months from Alvotech, where she has been the Head of Global Regulatory Affairs Biologics. Prior to Alvotech, she spent 15 years in various regulatory affairs functions at Roche, becoming Head of EU Regulatory Affairs in 2013, and five years in regulatory affairs at DSM Nutritional Products. Ms. Braun holds a PhD in pharmacy.

Thomas Jung

Dr. Thomas Jung is Chief Development Officer of the Company. He will lead the Company's clinical, preclinical and pharmaceutical development activities. He will join Auris Medical in September. Dr. Jung previously served as the Chief Medical Officer at Delenex Therapeutics AG and spent 13 years at Novartis, most recently as Head, Translational Medicine for the European Union.

Bettina Stubinski

Dr. Bettina Mirella Stubinski serves as Chief Medical Officer of Auris Medical Holding Ltd., since September 2013. She previously spent nine years with Merck Serono, Geneva (Switzerland), her last position there being Head of Global Clinical Development Multiple Sclerosis. Prior to Serono she was employed with Novartis Consumer Health, and previous to that led the Clinical Research department of Berlin Chemie, a division of the Menarini Group, which she joined in 1996. Dr. Stubinski holds an M.D. with specialization in Clinical Neurophysiology from the Medical Faculty of the University of Genova, Italy, and started her career as a practicing Neurologist. In 2014 Dr. Stubinski obtained an M.B.A. at MIT’s Sloan School of Management.

Wolfgang Arnold

Dr. Wolfgang Arnold serves as Non-Executive Independent Director of Auris Medical Holding Ltd. Dr. Arnold has been a member of our board of directors since 2007. He is a professor emeritus in otolaryngology and head and neck surgery, and an internationally renowned expert in the field of inner ear disorders. Dr. Arnold has authored or co-authored more than 365 peer-reviewed scientific and medical articles and more than 10 textbooks. From 1981 to 1992 he served as Head of the Department of Otorhinolaryngology, Head & Neck Surgery, Cantonal Hospital of Lucerne (Switzerland) and from 1992 to 2007 he served as Director of the Department of Otolaryngology, Head and Neck Surgery of the Technical University of Munich, Germany. He is still practicing today. Dr. Arnold holds an M.D. from the University of Munich.

Oliver Kubli

Mr. Oliver Kubli serves as Non-Executive Independent Director of Directors of Auris Medical AG. Mr. Kubli has been a member of our board of directors since June 2010. He is a Managing Director and Head Portfolio Management Healthcare Funds & Mandates at Bellevue Asset Management AG. Mr. Kubli is the Senior Portfolio Manager for several public health care funds. Prior to joining Bellevue Asset Management, Mr Kubli was Head Portfolio Management Healthcare Funds & Mandates of Adamant Biomedical Investments AG. Before joining Adamant in 2008, he held various management positions at ZKB and was responsible for the global health care sector within the bank’s Asset Management Division. Mr. Kubli started his career as a financial analyst and portfolio manager with UBS and Swiss Re. He is a chartered financial analyst (CFA) and holds a B.A. in Business Administration from the University of Applied Sciences, Zürich/Winterthur, Switzerland.

Berndt Modig

Mr. Berndt A.E. Modig serves as Non-Executive Independent Director of Auris Medical Holding Ltd. Mr. Modig was elected to our board of directors in 2015. Mr. Modig is the Managing Director of Schoodic Management BV and Pharvaris BV. He was the Chief Financial Officer of Prosensa Holding N.V., a company dedicated to the development of treatments of neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy, from 2010 up to its sale to Biomarin. Prior to that, he was the Chief Financial Officer of Jerini AG, another publicly listed biotechnology company, and held various management positions in industry, finance and private equity groups. He started his professional career in the auditing practice of Price Waterhouse. Berndt Modig is a member of the Board of Directors and the Audit Committee of Affimed N.V., a member of the Board of Directors and chairman of the Audit Committee of Axovant Sciences, Ltd., and a member of the Board of Directors of Onco BioTek. Mr. Modig is a Certified Public Accountant and has an M.B.A. from INSEAD.

Calvin Roberts

Dr. Calvin W. Roberts, M.D., serves as Non-Executive Independent Director of Auris Medical Holding Ltd. Dr. Roberts was elected to our board of directors in 2015. Mr. Roberts, M.D., is Chief Medical Officer at Bausch + Lomb and Senior Vice President and Chief Medical Officer, Eye Care of Valeant Pharmaceuticals. He joined Bausch + Lomb in 2011. Dr. Roberts is a specialist in cataract and refractive surgery and has been a pioneer in the use of ophthalmic non-steroidals. Since 1982 he has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University; in addition, he had a private ophthalmology practice in New York City between 1998 and 2008. He is the author of over 50 peer-reviewed articles. Dr. Roberts has been a member of the Board of Directors and the Audit Committee of Alimera Sciences, Inc., since it was founded in 2003.